Linked Data API

Filter

These are the filters currently being used to limit the search results. Click on the remove filter icon to remove the filter.

answer › answering member printed	George Freeman
hansard heading	Osteoporosis: Drugs

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are shown at the top of the list. Click on remove this sort to remove a sort and or to reverse the current sort order. Click on the remove all sorting icon to remove all the sorting. Note that sorting can significantly slow down the loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined views, but starred properties are always present no matter what the view. You can star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

Items per page

Choose how many items to view on each page. The more items you view, the longer the page will take to load.

Show Search Form

Search Results

registered interest

date

exactly:

or between:
and

answering body

answering dept id

answering dept short name

answering dept sort name

hansard heading

house id

legislature


pref label

question text

tabling member constituency

tabling member printed

uin

answer

is ministerial correction

date of answer

exactly:

or between:
and

answer text

answering member constituency

answering member printed

question first answered

question first ministerially corrected

answering member


label

previous answer version

answering member constituency

answering member printed

answering member


label

tabling member


label

100730

registered interest

date

23/10/2014

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Osteoporosis: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.

tabling member constituency

Leicester West

tabling member printed

Liz Kendall

uin

211735

answer

is ministerial correction

date of answer

29/10/2014

answer text

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships. £ million <table><tbody><tr><td> </td><td>2009-10</td><td>2010-11</td><td>2011-12</td><td>2012-13</td><td>2013-14</td></tr><tr><td colspan="6">Asthma</td></tr><tr><td>Medical Research Council</td><td><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></td><td><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></td><td><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></td><td><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></td><td><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></td></tr><tr><td>Other Research Councils and Innovate UK</td><td>0.0</td><td>0.1</td><td>0.3</td><td>1.5</td><td>0.8</td></tr><tr><td>National Institute for Health Research</td><td>2.6</td><td>3.4</td><td>2.4</td><td>3.4</td><td>3.8</td></tr><tr><td>Total</td><td><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></td><td><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></td><td><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></td><td><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></td><td><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></td></tr><tr><td colspan="6">Motor Neurone Research</td></tr><tr><td>Medical Research Council</td><td>7.0</td><td>7.5</td><td>4.2</td><td>4.1</td><td>3.6</td></tr><tr><td>Other Research Councils and Innovate UK</td><td>0.2</td><td>0.2</td><td>0.4</td><td>0.7</td><td>1.0</td></tr><tr><td>National Institute for Health Research</td><td>0.1</td><td>0.1</td><td>0.4</td><td>0.7</td><td>0.5</td></tr><tr><td>Total</td><td>7.3</td><td>7.8</td><td>5.0</td><td>5.5</td><td>5.1</td></tr><tr><td colspan="6">Osteoporosis</td></tr><tr><td>Medical Research Council</td><td>6.2</td><td>5.4</td><td>5.1</td><td>4.6</td><td>5.9</td></tr><tr><td>Other Research Councils and Innovate UK</td><td>0.0</td><td>0.0</td><td>0.1</td><td>0.4</td><td>1.0</td></tr><tr><td>National Institute for Health Research</td><td>0.3</td><td>0.7</td><td>0.8</td><td>1.3</td><td>1.8</td></tr><tr><td>Total</td><td>6.5</td><td>6.1</td><td>6.0</td><td>6.3</td><td>8.7</td></tr></tbody></table> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma. Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure. Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.

answering member constituency

Mid Norfolk

answering member printed

George Freeman

question first answered

29/10/2014 17:12:28

question first ministerially corrected

13/11/2014 10:22:56

answering member

4020

	label	Biography information for George Freeman

previous answer version

25123

answering member constituency

Mid Norfolk

answering member printed

George Freeman

answering member

4020

	label	Biography information for George Freeman

tabling member

4026

	label	Biography information for Liz Kendall

100720

registered interest

date

23/10/2014

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Osteoporosis: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years.

tabling member constituency

Leicester West

tabling member printed

Liz Kendall

uin

211731

answer

is ministerial correction

date of answer

30/10/2014

answer text

Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table. Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections: 6.6 Drugs affecting bone metabolism 9.5.1.1 Calcium supplements 9.6 Vitamins (colecalciferol and ergocalciferol only) <table><tbody><tr><td colspan="11">Cost of drugs for the treatment of osteoporosis, England1</td></tr><tr><td>Drug Name2</td><td colspan="5">Primary Care(£ million)</td><td colspan="5">Secondary Care(£ million)</td></tr><tr><td>Year</td><td>2009</td><td>2010</td><td>2011</td><td>2012</td><td>2013</td><td>2009</td><td>2010</td><td>2011</td><td>2012</td><td>2013</td></tr><tr><td>Alendronic Acid</td><td>14.0</td><td>12.4</td><td>10.8</td><td>9.7</td><td>8.9</td><td>0.8</td><td>0.6</td><td>0.5</td><td>0.5</td><td>0.4</td></tr><tr><td>Alendronic Acid and Colecalciferol</td><td>1.4</td><td>1.2</td><td>0.9</td><td>0.7</td><td>0.6</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>Calcitonin (Salmon)</td><td>0.3</td><td>0.3</td><td>0.2</td><td>0.2</td><td>0.1</td><td>0.0</td><td>0.1</td><td>0.1</td><td>0.1</td><td>0.1</td></tr><tr><td>Calcium</td><td>4.2</td><td>4.7</td><td>4.5</td><td>3.7</td><td>3.3</td><td>0.9</td><td>0.9</td><td>0.9</td><td>0.9</td><td>0.9</td></tr><tr><td>Calcium and Colecalciferol</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>2.2</td><td>2.2</td><td>2.1</td><td>2.2</td><td>2.3</td></tr><tr><td>Clodronic Acid</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>2.9</td><td>2.4</td><td>1.6</td><td>1.2</td><td>0.9</td></tr><tr><td>Colecalciferol</td><td>42.4</td><td>48.3</td><td>58.5</td><td>67.6</td><td>75.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.4</td><td>1.2</td></tr><tr><td>Denosumab</td><td>0.0</td><td>0.0</td><td>0.2</td><td>0.8</td><td>1.9</td><td>0.0</td><td>0.1</td><td>0.9</td><td>2.3</td><td>9.9</td></tr><tr><td>Disodium Etidronate</td><td>1.3</td><td>1.0</td><td>0.8</td><td>0.6</td><td>0.3</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>Ergocalciferol</td><td>4.3</td><td>7.8</td><td>8.0</td><td>7.0</td><td>6.1</td><td>0.1</td><td>0.1</td><td>0.1</td><td>0.2</td><td>0.3</td></tr><tr><td>Ibandronic Acid</td><td>12.1</td><td>12.1</td><td>11.4</td><td>10.6</td><td>4.7</td><td>2.1</td><td>2.0</td><td>1.8</td><td>1.5</td><td>0.9</td></tr><tr><td>Pamidronic Acid</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>9.6</td><td>9.1</td><td>9.4</td><td>9.4</td><td>8.7</td></tr><tr><td>Risedronate Sodium and Risedronate Acid</td><td>27.9</td><td>22.9</td><td>11.6</td><td>2.4</td><td>2.0</td><td>0.8</td><td>0.6</td><td>0.3</td><td>0.1</td><td>0.1</td></tr><tr><td>Sodium Clodronate</td><td>7.8</td><td>7.2</td><td>6.3</td><td>5.5</td><td>4.3</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>Strontium Ranelate</td><td>7.0</td><td>7.8</td><td>9.0</td><td>9.2</td><td>7.3</td><td>0.6</td><td>0.6</td><td>0.6</td><td>0.5</td><td>0.2</td></tr><tr><td>Teriparatide</td><td>0.3</td><td>0.4</td><td>0.4</td><td>0.5</td><td>0.6</td><td>2.7</td><td>2.8</td><td>2.7</td><td>3.1</td><td>3.2</td></tr><tr><td>Zoledronic Acid</td><td>0.1</td><td>0.1</td><td>0.1</td><td>0.1</td><td>0.1</td><td>16.7</td><td>18.0</td><td>20.9</td><td>23.7</td><td>25.7</td></tr><tr><td>Other Calcium Supplement Preps</td><td>0.5</td><td>0.6</td><td>0.6</td><td>0.5</td><td>0.5</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td></tr><tr><td>Other drugs3</td><td>0.2</td><td>0.1</td><td>0.1</td><td>0.0</td><td>0.0</td><td>0.2</td><td>0.1</td><td>0.1</td><td>0.1</td><td>0.0</td></tr><tr><td>TOTAL</td><td>123.8</td><td>126.8</td><td>123.4</td><td>119.1</td><td>115.4</td><td>39.6</td><td>39.6</td><td>42.3</td><td>46.2</td><td>55.0</td></tr></tbody></table> 1 Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding. 2 The patent for some of these drugs may have expired during this period. 3 “Other drugs” includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations. Source: Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care) Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care) Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.

answering member constituency

Mid Norfolk

answering member printed

George Freeman

question first answered

30/10/2014 16:09:20

answering member

4020

	label	Biography information for George Freeman

tabling member

4026

	label	Biography information for Liz Kendall

427753

registered interest

date

10/11/2015

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Osteoporosis: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, if he will discuss with the Royal Colleges the potential side effects of osteoporosis drugs on (a) jaw and (b) general bone health.

tabling member constituency

Strangford

tabling member printed

Jim Shannon

uin

15996

answer

is ministerial correction

date of answer

18/11/2015

answer text

As with all medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Government’s independent expert advisory body the Commission on Human Medicines (CHM) keep the safety of osteoporosis drugs under continual review including their effects on the jaw and on bone health. The MHRA, together with the CHM, ensures that the product information for osteoporosis medicines contains up to date information and issues updated advice as appropriate.Warnings about the risks of osteonecrosis of the jaw (severe bone damage in the jaw) and atypical fractures of the femur (unusual fracture of the thigh bone) are included in the product information (Summary of Product Characteristics for healthcare professionals and Patient Information Leaflet for patients) for all medicines containing bisphosphonates or denosumab which are used in the treatment of osteoporosis. New information and advice on these risks have been communicated to healthcare professionals in the MHRAsafety bulletin in 2006, 2007, 2009, 2011, 2013 and 2014 as new information has become available. A patient reminder card on the risk of osteonecrosis of the jaw is currently being introduced for patients treated with denosumab and bisphosphonates given by injection and healthcare professionals have been informed of this new measure via the MHRA bulletin.Information about the recognised risks of osteonecrosis of the jaw and atypical fractures of the femur with bisphosphonates and denosumab is also included in the 2014 ‘Osteoporosis - Clinical Guideline for prevention and treatment’ developed by the National Osteoporosis Guideline Group which includes the Royal College of Physicians.

answering member constituency

Mid Norfolk

answering member printed

George Freeman

question first answered

18/11/2015 09:10:29

answering member

4020

	label	Biography information for George Freeman

tabling member

4131

	label	Biography information for Jim Shannon